Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 1.00 |
| ▸ | CSF1R | P07333 | 6/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6182107 | 0.98 | EGFR (0.97) | EGFRCSF1RPDGFRBPDGFRAPDE5A | |
| SCHEMBL3119399 | 0.88 | EGFR (0.79) | EGFRCSF1RPDGFRBPDGFRAHDAC1 | |
| SCHEMBL18088097 | 0.87 | EGFR (0.77) | EGFRCSF1RPDGFRBPDGFRAHDAC1 | |
| SCHEMBL3112121 | 0.84 | EGFR (0.72) | EGFRCSF1RPDGFRBPDGFRAHDAC1 | |
| SCHEMBL3122421 | 0.83 | EGFR (0.70) | EGFRCSF1RPDGFRBPDGFRA | |
| Hydrochloric Acid SCHEMBL6181651 | 0.82 | EGFR (0.68) | EGFRCSF1RPDGFRBPDGFRA | |
| SCHEMBL8900055 | 0.81 | EGFR (0.69) | EGFRCSF1R | |
| SCHEMBL3123760 | 0.81 | CSF1R (1.00) | EGFRCSF1RPDGFRBPDGFRA | |
| SCHEMBL4354965 | 0.81 | EGFR (0.70) | EGFRCSF1RPDGFRBPDGFRA | |
| SCHEMBL11083826 | 0.81 | CSF1R (0.79) | EGFRCSF1RPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2008-02-14 | — | — | US | disclosed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0520722-B1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LTD (GB) | 1996-12-27 | — | — | EP | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
| EP-0520722-A1 | Therapeutic preparations containing quinazoline derivatives | ZENECA LIMITED (GB) | 1992-12-30 | — | — | EP | disclosed |
| US-4464375-A | ANALGESIC, ANTIINFLAMMATORY | SANKYO CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4322420-A | Method of using 4-anilinoquinazoline derivatives as analgesic and anti-inflammatory agents | SANKYO COMPANY LIMITED (JP) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885CSF1R 3082/4885PDGFRB 2620/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | EGFR 3147/4885CSF1R 3520/4885PDGFRB 2783/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2648/4885CSF1R 3139/4885PDGFRB 2627/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885CSF1R 3082/4885PDGFRB 2620/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885CSF1R 3082/4885PDGFRB 2620/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | EGFR 2915/4885CSF1R 3082/4885PDGFRB 2620/4885 |
| US-20080039479-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885CSF1R 3082/4885PDGFRB 2620/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885CSF1R 3082/4885PDGFRB 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.